MelanoDB: Database files of clinical and molecular1 features of advanced melanoma patients treated with2 MAPK inhibitors

MAPK inhibitors have significantly improved overall survival in patients with metastatic melanoma disease but their efficacy is still limited by primary or acquired resistance. Several studies have attempted to predict response to MAPK inhibitor therapy, however the lack of a consistent cohort prevents better definition of associations between treatment efficacy and clinical and/or molecular features. Here, we present MelanoDB, a collection of patients with metastatic melanoma treated with MAPK inhibitors. We formatted data from 8 different studies for a total of 417 cases to gather common clinical and molecular features. Whole or partial exome sequencing is available for 191 cases and gene expression for 132 cases. We provide a web application to explore the integrated data and its distribution among the collected studies, and we share this dataset to the scientific community according to FAIR principles

These data are available under the licence CC-BY-SA.

Here we provide a web application viewer of the database content: http://melanodb-ircm.montp.inserm.fr/

You are requested to cite this repository in the case of using these data in a publication.